Effects of Coenzyme Q10 in PSP and CBD
Effects of Coenzyme Q10 in PSP and CBD, A Randomized, Placebo-Controlled, Double Blind Cross Over Pilot Study
To compare the efficacy, safety and tolerability of Coenzyme Q 10 versus placebo in patients with atypical parkinsonian syndromes corticobasal degeneration (CBD) and progressive supranuclear palsy (PSP) ).
Phase 2/Phase 3
Progressive Supranuclear Palsy
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
Inclusion Criteria: - Patients fulfilling the diagnostic criteria of PSP and CBD (above) and who were diagnosed within the past 5 years - Age > 40 - Subjects receiving anticholinergics, amantadine, dopamine agonists, carbidopa/levodopa, eldepryl, or comtan must be on a stable dose for at least 30 days prior to baseline visit. - Patients agreeable to participate in the study. Exclusion Criteria: - Prior or concurrent therapy with anticholinergics, amantadine,a dopamine agonist,carbidopa/levodopa or comtan within 30 days of the baseline visit. - Parkinsons disease or any other atypical parkinsonism; Parkinsonism due to drugs. - History of pallidotomy, thalamotomy, deep brain stimulation or fetal tissue transplant. - Previous use of coenzyme Q10 within 60 days of the baseline visit.
40 Years - N/A
Accepts Healthy Volunteers
Diana Apetauerova, MD, ,
CoQ10 with PSP/CBD
Diana Apetauerova, MD, Principal Investigator, Lahey Clinic